James N Armitage
Overview
Explore the profile of James N Armitage including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
25
Citations
844
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Horvat-Menih I, McLean M, Zamora-Morales M, Wylot M, Kaggie J, Khan A, et al.
BMJ Open
. 2024 Oct;
14(10):e083980.
PMID: 39461869
Introduction: Localised renal masses are an increasing burden on healthcare due to the rising number of cases. However, conventional imaging cannot reliably distinguish between benign and malignant renal masses, and...
2.
Blackmur J, Armitage J, Jones J, Riddick A, Mitchell T, Ince W, et al.
BJU Int
. 2024 Jul;
PMID: 39014977
No abstract available.
3.
Horvat-Menih I, Li H, Priest A, Li S, Gill A, Mendichovszky I, et al.
Eur Radiol Exp
. 2024 Jul;
8(1):76.
PMID: 38981998
Background: Clinical imaging tools to probe aggressiveness of renal masses are lacking, and T2-weighted imaging as an integral part of magnetic resonance imaging protocol only provides qualitative information. We developed...
4.
Li R, Ferdinand J, Loudon K, Bowyer G, Laidlaw S, Muyas F, et al.
Cancer Cell
. 2022 Nov;
40(12):1583-1599.e10.
PMID: 36423636
Tumor behavior is intricately dependent on the oncogenic properties of cancer cells and their multi-cellular interactions. To understand these dependencies within the wider microenvironment, we studied over 270,000 single-cell transcriptomes...
5.
Ursprung S, Woitek R, McLean M, Priest A, Crispin-Ortuzar M, Brodie C, et al.
Cancers (Basel)
. 2022 Jan;
14(2).
PMID: 35053497
Differentiating aggressive clear cell renal cell carcinoma (ccRCC) from indolent lesions is challenging using conventional imaging. This work prospectively compared the metabolic imaging phenotype of renal tumors using carbon-13 MRI...
6.
Welsh S, Thompson N, Warren A, Priest A, Barrett T, Ursprung S, et al.
BJU Int
. 2021 Sep;
130(2):244-253.
PMID: 34549873
Objective: To explore translational biological and imaging biomarkers for sunitinib treatment before and after debulking nephrectomy in the NeoSun (European Union Drug Regulating Authorities Clinical Trials Database [EudraCT] number: 2005-004502-82)...
7.
Smith C, Moser T, Mouliere F, Field-Rayner J, Eldridge M, Riediger A, et al.
Genome Med
. 2020 Mar;
12(1):23.
PMID: 32111235
Background: Cell-free tumor-derived DNA (ctDNA) allows non-invasive monitoring of cancers, but its utility in renal cell cancer (RCC) has not been established. Methods: Here, a combination of untargeted and targeted...
8.
Stewart B, Ferdinand J, Young M, Mitchell T, Loudon K, Riding A, et al.
Science
. 2019 Oct;
365(6460):1461-1466.
PMID: 31604275
Tissue-resident immune cells are important for organ homeostasis and defense. The epithelium may contribute to these functions directly or by cross-talk with immune cells. We used single-cell RNA sequencing to...
9.
Klatte T, Gallagher K, Afferi L, Volpe A, Kroeger N, Ribback S, et al.
BMC Med
. 2019 Oct;
17(1):182.
PMID: 31578141
Background: The current World Health Organization classification recognises 12 major subtypes of renal cell carcinoma (RCC). Although these subtypes differ on molecular and clinical levels, they are generally managed as...
10.
Impact of hospital nephrectomy volume on intermediate- to long-term survival in renal cell carcinoma
Hsu R, Barclay M, Loughran M, Lyratzopoulos G, Gnanapragasam V, Armitage J
BJU Int
. 2019 Jun;
125(1):56-63.
PMID: 31206987
Objective: To evaluate the relationship between hospital volume and intermediate- and long-term patient survival for patients undergoing nephrectomy for renal cell carcinoma (RCC). Patients And Methods: Adult patients with RCC...